Our Science

Our Boltbody™ platform consists of systemically delivered Immune-Stimulating Antibody Conjugates (ISAC). We conjugate tumor-targeting antibodies to powerful immune stimulants such as TLR agonists, proven to convert cold tumors into immunologically hot tumors, and have demonstrated that Boltbody™ ISACs eliminate tumors in preclinical models following systemic administration.

The Boltbody™ platform reinvigorates the immune system and builds on our understanding of how dendritic and other myeloid cells generate effective anti-tumor immunity. Boltbody™ ISACs are a unique class of immuno-oncology therapies whose capabilities hold the promise of generating systemic immunological memory with durable clinical benefit.

Dr. Edgar G. Engleman, M.D., Director, Immunology & Immunotherapy of Cancer Programs, Stanford Cancer Institute. Bolt Founder and Board Member.


News & Publications

Our Team




Bolt Biotherapeutics is a vibrant biotechnology company actively developing novel immunotherapeutics based upon its platform technology for multiple types of cancer. Located in the San Francisco Bay Area, Bolt is led by a team with extensive oncology drug development experience and is seeking bright, self-motivated individuals who share their passion for bringing novel and curative biotherapies to patients in need. If you enjoy a collaborative and fun environment with all the benefits and challenges that come with working at a cutting-edge biotherapeutics company, please contact us at 650.665.9295 or jobs@boltbio.com for more information.

Here are some positions we’re hiring:

Senior Preclinical Research Associate / Scientist I
Quality Assurance Associate, Process Development
Senior Research Associate, Target Validation
Scientist / Sr. Scientist: Biomarkers and Translational Science
Senior Project Manager / Associate Director of Project Management

Contact Us

4 + 0 = ?

Boltbody™ Immune-Stimulating Antibody Conjugates

Bolt Biotherapeutics, Inc.
640 Galveston Drive
Redwood City, CA 94063